Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
The Role of Tim-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy? Publisher



Ganjalikhani Hakemi M1 ; Jafarinia M1 ; Azizi M1 ; Rezaeepoor M2 ; Isayev O3, 4 ; Bazhin AV5, 6
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Immunology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Immunology, School of Medicine, Hamedan University of Medical Sciences, Hamedan, Iran
  3. 3. Department of Cytology, Embryology and Histology, Medical University, Baku, Azerbaijan
  4. 4. Genetic Resources Institute, Azerbaijan National Academy of Scince, Baku, Azerbaijan
  5. 5. Department of General, Visceral and Transplant Surgery, Ludwig-Maximilians University of Munich, Munich, Germany
  6. 6. German Cancer Consortium (DKTK), Munich, Germany

Source: Frontiers in Oncology Published:2020


Abstract

One of the most common tumors in the world is hepatocellular carcinoma (HCC), and its mortality rates are still on the rise, so addressing it is considered an important challenge for universal health. Despite the various treatments that have been developed over the past decades, the prognosis for advanced liver cancer is still poor. Recently, tumor immunotherapy has opened new opportunities for suppression of tumor progression, recurrence, and metastasis. Besides this, investigation into this malignancy due to high immune checkpoint expression and the change of immunometabolic programming in immune cells and tumor cells is highly considered. Because anti-cytotoxic T lymphocyte–associated protein (CTLA)-4 antibodies and anti-programmed cell death protein (PD)-1 antibodies have shown therapeutic effects in various cancers, studies have shown that T cell immunoglobulin mucin-3 (TIM-3), a new immune checkpoint molecule, plays an important role in the development of HCC. In this review, we summarize the recent findings on signal transduction events of TIM-3, its role as a checkpoint target for HCC therapy, and the immunometabolic situation in the progression of HCC. © Copyright © 2020 Ganjalikhani Hakemi, Jafarinia, Azizi, Rezaeepoor, Isayev and Bazhin.
Related Docs
View other Related Docs
1. Tim-3 in Leukemia; Immune Response and Beyond, Frontiers in Oncology (2021)
2. Preparation and Characterization of a Novel Nanobody Against T-Cell Immunoglobulin and Mucin-3 (Tim-3), Iranian Journal of Basic Medical Sciences (2016)
3. Tim3 and Pd-1 As a Therapeutic and Prognostic Targets in Colorectal Cancer: Relationship With Sidedness, Clinicopathological Parameters, and Survival, Frontiers in Oncology (2023)
4. Study of T-Cell Immunoglobulin and Mucin Domain-3 Expression Profile in Peripheral Blood and Bone Marrow of Human Acute Lymphoblastic Leukemia Patients, Journal of Research in Medical Sciences (2020)
5. The Role of Immune Regulatory Molecules in Multiple Sclerosis, Journal of Neuroimmunology (2019)
6. Tim-3/Gal-9 Interaction Affects Glucose and Lipid Metabolism in Acute Myeloid Leukemia Cell Lines, Frontiers in Immunology (2023)
7. Silencing of Tim-3 Expression by Mir-326 Affects Apoptosis and Proliferation of Human Hl-60 Leukemia Cell Line, UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi (2018)
8. Immune Checkpoint Inhibition for the Treatment of Cancers: An Update and Critical Review of Ongoing Clinical Trials, Clinical Immunology (2021)
Experts (# of related papers)
View all Related Experts
Mazdak Ganjalikhani Hakemi (20)
Hossein Khanahmad (9)
Other Related Docs
9. Tim-3/Galectin-9 Interaction and Glutamine Metabolism in Aml Cell Lines, Hl-60 and Thp-1, BMC Cancer (2024)
10. Immunotherapy a New Hope for Cancer Treatment: A Review, Pakistan Journal of Biological Sciences (2018)
11. Evaluation of the Effect of Tim-3 Suppression by Mir-498 and Its Effect on Apoptosis and Proliferation Rate of Hl-60 Cell Line, Pathology Research and Practice (2018)
12. Producing Recombinant Hek293 T-Cells With High Expression of T-Cell Immunoglobulin and Mucin Domain-3 (Tim3) Protein, Journal of Isfahan Medical School (2015)
13. Targeting Immune Checkpoints: How to Use Natural Killer Cells for Fighting Against Solid Tumors, Cancer Communications (2023)
14. Stimulation of Camel Polyclonal Antibody Against Human T Cell Immunoglobulin and Mucin 3, Iranian Journal of Biotechnology (2017)
15. Evaluating T-Cell Immunoglobulin Mucin-3 (Tim-3) Receptor in the Growth Inhibition of Acute Lymphoblastic Leukemia (All) Cell Lines, Journal of Isfahan Medical School (2015)
16. The Role of Bone Marrow Microenvironment (Bmm) Cells in Acute Myeloid Leukemia (Aml) Progression: Immune Checkpoints, Metabolic Checkpoints, and Signaling Pathways, Cell Communication and Signaling (2023)
17. The Kinetics of Inhibitory Immune Checkpoints During and Post-Covid-19: The Knowns and Unknowns, Clinical and Experimental Medicine (2023)
18. Comparing the Frequency of Tim-3 Polymorphism in Multiple Sclerosis Patients With Healthy Controls, Journal of Isfahan Medical School (2015)
19. Negative Regulation of Tim-3 Expression in Aml Cell Line (Hl-60) Using Mir-330-5P, British Journal of Biomedical Science (2016)
20. Immunologic Tumor Microenvironment Modulators for Turning Cold Tumors Hot, Cancer Communications (2024)
21. Cutting Edge: Metabolic Immune Reprogramming, Reactive Oxygen Species, and Cancer, Journal of Cellular Physiology (2021)
22. The +4259A>C Polymorphism of Tim-3 But Not -1637C>T Polymorphism of Tim-1 Is Associated With Multiple Sclerosis in Isfahan Population, Multiple Sclerosis and Related Disorders (2017)
23. The Frequency of Tim-3-1541C>T Polymorphisms and Its Association With Multiple Sclerosis, Journal of Isfahan Medical School (2015)
24. Investigating the Effect of Cgrp78 Vaccine Against Different Cancer Cells and Its Role in Reducing Melanoma Metastasis, Research in Pharmaceutical Sciences (2024)
25. Producing Soluble Human Programmed Cell Death Protein-1: A Natural Supporter for Cd4+T Cell Cytotoxicity and Tumor Cells Apoptosis, Iranian Journal of Biotechnology (2019)
26. Construction and Periplasmic Expression of a Bispecific Tandem Scfv for Dual Targeting of Immune Checkpoints, Advanced Biomedical Research (2023)
27. Changes in Immune Profile Affect Disease Progression in Hepatocellular Carcinoma, International Journal of Immunopathology and Pharmacology (2022)
28. An in Silico Investigation on the Binding Site Preference of Pd-1 and Pd-L1 for Designing Antibodies for Targeted Cancer Therapy, PLoS ONE (2024)
29. Combination Therapy With Nivolumab (Anti-Pd-1 Monoclonal Antibody): A New Era in Tumor Immunotherapy, International Immunopharmacology (2022)
30. Identification of B and T Cell Epitope Based Peptide Vaccine From Igf-1 Receptor in Breast Cancer, Journal of Molecular Graphics and Modelling (2017)
31. Bioinformatics Design of a Peptide Vaccine Containing Sarcoma Antigen Ny-Sar-35 Epitopes Against Breast Cancer and Evaluation of Its Immunological Function in Balb/C Mouse Model, PLoS ONE (2024)
32. Investigating the Dynamic Interplay Between Cellular Immunity and Tumor Cells in the Fight Against Cancer: An Updated Comprehensive Review, Iranian Journal of Blood and Cancer (2024)
33. Cancer Vaccine in Cold Tumors: Clinical Landscape, Challenges, and Opportunities, Current Cancer Drug Targets (2022)
34. In Vitro Selective Depletion of Cd4+Cd25+ Regulatory T-Cells From Pbmc Using Anti-Tac-Sap, Journal of Immunotoxicology (2012)
35. Immune Evader Cancer Stem Cells Direct the Perspective Approaches to Cancer Immunotherapy, Stem Cell Research and Therapy (2022)
36. Enhanced in Vivo Anti-Tumor Efficacy of Whole Tumor Lysate in Combination With Whole Tumor Cell-Specific Polyclonal Antibody, Research in Pharmaceutical Sciences (2023)
37. Don't Eat Me/Eat Me Signals As a Novel Strategy in Cancer Immunotherapy, Heliyon (2023)
38. Engaging Stemness Improves Cancer Immunotherapy, Cancer Letters (2023)
39. The Mir-125A-3P Inhibits Tim-3 Expression in Aml Cell Line Hl-60 in Vitro, Indian Journal of Hematology and Blood Transfusion (2017)
40. Comparison of Laboratory Methods for the Clinical Follow up of Checkpoint Blockade Therapies in Leukemia: Current Status and Challenges Ahead, Frontiers in Oncology (2022)
41. Exploring the Cancer-Testis Antigen Boris to Design a Novel Multi-Epitope Vaccine Against Breast Cancer Based on Immunoinformatics Approaches, Journal of Biomolecular Structure and Dynamics (2022)
42. The Role of Immune Regulatory Molecules in Covid-19, Viral Immunology (2022)
43. Tumor-Infiltrating Myeloid Cells; Mechanisms, Functional Significance, and Targeting in Cancer Therapy, Cellular Oncology (2025)
44. Nivolumab Plus Ipilimumab Combination Therapy in Cancer: Current Evidence to Date, International Immunopharmacology (2023)
45. A Comprehensive Study on the Prognostic Value and Clinicopathological Significance of Different Immune Checkpoints in Patients With Colorectal Cancer: A Systematic Review and Meta-Analysis, Current Therapeutic Research - Clinical and Experimental (2024)
46. In Silico Analysis of Transmembrane Protein 31 (Tmem31)Antigen to Design Novel Multiepitope Peptide and Dna Cancer Vaccines Against Melanoma, Molecular Immunology (2019)
47. Clinical Combinatorial Treatments Based on Cancer Vaccines: Combination With Checkpoint Inhibitors and Beyond, Current Drug Targets (2022)
48. The Molecular Perspective on the Melanoma and Genome Engineering of T-Cells in Targeting Therapy, Environmental Research (2023)
49. The Relationship Between Programmed Cell Death Receptor-1 Expression in Colon Tumoral Tissue and Clinical and Pathological Characteristics of Patients With Colon Cancer; [ارتباط بیان گیرنده ی مرگ برنامه ریزی شده 1 در بافت تومورال روده ی بزرگ با ویژگی های بالینی و آسیب شناسی بیماران مبتلا به سرطان روده ی بزرگ], Journal of Isfahan Medical School (2023)
50. Development of a Stable Cell Line, Overexpressing Human T-Cell Immunoglobulin Mucin 1, Iranian Journal of Biotechnology (2015)